Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time

Thank you for participating in this symposium.

To claim CE credit, please complete the form below. Approximately 4 weeks after completion, a certificate will be emailed to you.

Contact education@nccn.org with any questions.

Please rate your overall satisfaction with the activity. *

Very satisfied

Satisfied

Dissatisfied

Very dissatisfied

Please explain.

The faculty were effective in presenting the material. *

Please rate the extent to which you agree or disagree.

	Strongly agree	Agree	Disagree	Strongly disagree
Jeremy S. Abramson, MD, MMSc	Jeremy S. Abramson, MD, MMSc - Strongly agree	Jeremy S. Abramson, MD, MMSc - Agree	Jeremy S. Abramson, MD, MMSc - Disagree	Jeremy S. Abramson, MD, MMSc - Strongly disagree
Farrukh Awan, MD	Farrukh Awan, MD - Strongly agree	Farrukh Awan, MD - Agree	Farrukh Awan, MD - Disagree	Farrukh Awan, MD - Strongly disagree
Shuo Ma, MD, PhD	Shuo Ma, MD, PhD - Strongly agree	Shuo Ma, MD, PhD - Agree	Shuo Ma, MD, PhD - Disagree	Shuo Ma, MD, PhD - Strongly disagree

Additional comments about the faculty:

This activity was free of commercial bias. *

Please rate the extent to which you agree or disagree.

Strongly agree

Agree

Disagree

Strongly disagree

If commercial bias was noted, please explain. *

The activity addressed the following objectives: *

Please rate the extent to which you agree or disagree.

	Strongly agree	Agree	Disagree	Strongly disagree
Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference	Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference - Strongly agree	Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference - Agree	Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference - Disagree	Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference - Strongly disagree
Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action	Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action - Strongly agree	Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action - Agree	Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action - Disagree	Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action - Strongly disagree
Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)	Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy) - Strongly agree	Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy) - Agree	Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy) - Disagree	Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy) - Strongly disagree
Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy	Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy - Strongly agree	Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy - Agree	Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy - Disagree	Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy - Strongly disagree

Since completing this activity, are you more confident about your ability to do the following: *

	Yes	No
Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference	Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference - Yes	Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference - No
Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action	Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action - Yes	Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action - No
Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)	Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy) - Yes	Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy) - No
Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy	Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy - Yes	Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy - No

The activity: *

Please rate the extent to which you agree or disagree.

	Strongly agree	Agree	Disagree	Strongly disagree
Increased my knowledge of the presented topic.	Increased my knowledge of the presented topic. - Strongly agree	Increased my knowledge of the presented topic. - Agree	Increased my knowledge of the presented topic. - Disagree	Increased my knowledge of the presented topic. - Strongly disagree
Improved my professional competence and/or performance.	Improved my professional competence and/or performance. - Strongly agree	Improved my professional competence and/or performance. - Agree	Improved my professional competence and/or performance. - Disagree	Improved my professional competence and/or performance. - Strongly disagree
Provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, question and answer).	Provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, question and answer). - Strongly agree	Provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, question and answer). - Agree	Provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, question and answer). - Disagree	Provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, question and answer). - Strongly disagree
Provided content that was fair, balanced, and scientifically rigorous.	Provided content that was fair, balanced, and scientifically rigorous. - Strongly agree	Provided content that was fair, balanced, and scientifically rigorous. - Agree	Provided content that was fair, balanced, and scientifically rigorous. - Disagree	Provided content that was fair, balanced, and scientifically rigorous. - Strongly disagree

Do you work as part of an interprofessional health care team? *

Yes

After participation in this activity: *

Please rate the extent to which you agree or disagree.

	Strongly agree	Agree	Disagree	Strongly disagree
I have a better understanding of my role as a member of the health care team	I have a better understanding of my role as a member of the health care team - Strongly agree	I have a better understanding of my role as a member of the health care team - Agree	I have a better understanding of my role as a member of the health care team - Disagree	I have a better understanding of my role as a member of the health care team - Strongly disagree
I have a better understanding of the roles of others on the health care team.	I have a better understanding of the roles of others on the health care team. - Strongly agree	I have a better understanding of the roles of others on the health care team. - Agree	I have a better understanding of the roles of others on the health care team. - Disagree	I have a better understanding of the roles of others on the health care team. - Strongly disagree
My ability to work as part of the health care team is improved.	My ability to work as part of the health care team is improved. - Strongly agree	My ability to work as part of the health care team is improved. - Agree	My ability to work as part of the health care team is improved. - Disagree	My ability to work as part of the health care team is improved. - Strongly disagree

If you disagreed above, please explain your reason(s) for doing so:

Of the patients you see in one week’s time, how many are likely to benefit from the information you learned in this activity? *

Please provide whole numbers only. Do not provide a range. Enter 0 if you do not see patients.

Do you feel that your participation in this activity will have a positive impact on the community and/or population health of patients with cancer? *

Yes

N/A - I do not see patients

Do you feel that your participation in this activity will lead to improvements in health care quality? *

Yes

After participation in this activity, do you intend to make changes in your professional practice? *

Yes

I already practice these recommendations

No, there are too many barriers

Please select any of the following changes that you may implement in your professional practice: *

Select all that apply.

Apply latest NCCN Guidelines

Better communication of treatment plans with patients and/or caregivers

Better communication with other members of the health care team

Change in diagnostic testing

Change in non-pharmaceutical therapy

Change in pharmaceutical therapy

Discuss the availability of clinical trials with patients and/or caregivers

Educate the health care team on new information

Improve shared decision making with patients and/or caregivers

Please select any of the following barriers that you may experience in implementing these changes in your professional practice: *

Select all that apply.

Administrative/leadership/health system barriers

As part of the health care team, we need additional education to improve performance of the team.

I need additional education to improve my performance.

Ineffective communication among health care team members

Insurance/financial issues

Patient adherence/compliance issues

Time/resource constraints

What was the most useful thing you learned in this activity that will improve your professional practice?

Are there any issues (clinical or otherwise) that you feel should have been addressed in this educational activity?

Which clinical setting best describes your practice? *

Academic or Teaching Hospital Cancer Center

Local or Community Hospital/Community Cancer Center

Government/VA/Military

Group or Private Practice

Insurance Company/Managed Care Organization

Industry (Pharmaceutical/Biotech)

Please enter your name and credentials for your certificate. *

Please select the type of credit you are requesting. *

AMA PRA Category 1 Credit™

ANCC contact hours

AAPA Category 1 CME credit

ACPE contact hours

Participation credit

Please enter your NABP ID number. *

Please enter your date of birth in the format MMDD. *

Please enter your email address. *

Leave this field blank

You are here

Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time